CN103961400A - Compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry - Google Patents
Compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry Download PDFInfo
- Publication number
- CN103961400A CN103961400A CN201410165137.2A CN201410165137A CN103961400A CN 103961400 A CN103961400 A CN 103961400A CN 201410165137 A CN201410165137 A CN 201410165137A CN 103961400 A CN103961400 A CN 103961400A
- Authority
- CN
- China
- Prior art keywords
- herba lycopi
- group
- parts
- days
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry. The compound medicine comprises the following raw materials in parts by weight: 3 to 20 parts of florfenicol and 10 to 180 parts of herba lycopi. The raw materials are uniformly mixed to be prepared into powder, tablets, an oral liquid or granules to be added into livestock and poultry feed according to the additive amount of 0.1-5 g/kg for feeding, and drug resistance of antibacterial on bacteria can be reversed, so that the treatment effect of the antibacterial can be improved, the medicine cost can be greatly reduced, and higher economic benefits are created for farmers.
Description
The present invention is that the denomination of invention of application on 03 18th, 2013 is " a kind of Herba Lycopi of containing treats the compound of poultry coli-infection disease ", the divisional application that application number is 201310085612.0.
Technical field
The present invention relates to the poultry compound medicine of a kind of Herba Lycopi of containing and florfenicol.
Background technology
Escherichia coli are common conditioned pathogens, also be normal a kind of disease of sending out, can the former multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis of having carried out the coffin upon burial, also can secondary or mixed in virosis, cause huge economic loss to aquaculture.Wherein amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, the beta-lactam lopps antibiotic such as ampicillin/sulbactam are the conventional important drugs of this disease of control, along with cultivation scale intensive degree is more and more large, medication is more and more spread unchecked, its Resistant strain is more and more many, more about Drug Resistance of E. coli report, one of main mechanism that studies confirm that at present drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), can be hydrolyzed more by force and fast beta-lactam nucleus, make this class antibiotic lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and ESBLs is not only to cephalo three generations and aztreonam drug resistance, and aminoglycoside, quinolones and sulfonamides are to crossing drug resistant, only to carbapenems, a mould alkene class medicaments insensitive.Current many documents have reported that colibacillary multi-drug resistant and generation ESBLs have substantial connection, comparatively pay close attention to it both at home and abroad.The detection, extraction, enzyme that I have carried out chicken source pathogenic bacterium ESBLs presses down the researchs such as enzyme protection effect to antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine.To part ESBLs, colibacillary drug sensitive test shows, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain.Result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur in addition, and also to multiple antimicrobial drug drug resistances such as fluoroquinolones, aminoglycoside and sulfonamides, be serious multidrug resistant, colibacillary drug resistance causes to raiser's drug cost to be increased, extend the course for the treatment of of treatment, mortality of livestock increases, and brings higher expenses for medicine cost and economic loss to production.Therefore, suddenly in actual production waiting to need a kind of to no matter whether, the escherichia coli of drug resistance can have the medicine of better therapeutical effect, to shorten the course for the treatment of of treatment, reduce mortality rate, reduce economic loss, is that raiser creates higher economic benefit.
Summary of the invention
The object of this invention is to provide the poultry compound medicine of a kind of Herba Lycopi of containing and florfenicol, can kill quickly antibacterial, overcome large, the residual height of weak curative effect, consumption and the high defect of cost that antimicrobial drug treatment causes due to drug resistance problem.
The present invention is achieved through the following technical solutions above-mentioned purpose: a kind of poultry compound medicine that contains Herba Lycopi and florfenicol, is made up of the raw material of following weight ratio: florfenicol 3-20 part, Herba Lycopi 10-180 part.
The compound method of described compound medicine is: Herba Lycopi is pulverized, cross after 60 mesh sieves, then put into blender with pulverous antimicrobial drug according to described parts by weight of raw materials ratio and mix, be prepared into powder, tablet, oral liquid or granule.
The beneficial effect that the present invention compared with prior art had is: in antimicrobial drug, add after Herba Lycopi, can reverse the drug resistance of bacteria medicine, thereby the therapeutic effect that improves antimicrobial drug, significantly reduces drug cost, for raiser creates higher economic benefit.
Detailed description of the invention:
Antimicrobial drug itself has the colibacillary effect for the treatment of, but because the escherichia coli that produce ESBLs drug resistant gene have stronger drug resistance, causes antimicrobial drug not show good therapeutic effect in normal using dosage situation.
In order to verify the drug resistance inversion effect of Herba Lycopi to antimicrobial drug, applicant adopts microtest tube doubling dilution on 96 orifice plates, first measure antimicrobial drug to producing minimal inhibitory concentration and the subinhibitory concentration of Herba Lycopi to product ESBLs e. coli strains of ESBLs e. coli strains, then in culture medium, added the Herba Lycopi of subinhibitory concentration to reuse the minimal inhibitory concentration of microtest tube doubling dilution cultivation mensuration antimicrobial drug; Utilize continuous passage method in the culture medium that is added with same subinhibitory concentration Herba Lycopi and same concentration antimicrobial drug to producing the cultivation of going down to posterity of ESBLs e. coli strains, until the antimicrobial drug minimal inhibitory concentration observing diminishes more than 4 times compared with before going down to posterity, can be judged as Herba Lycopi has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in the table:
Subinhibitory concentration Herba Lycopi culture medium goes down to posterity and causes the variation (ug/ml) of producing ESBLs escherichia coli Western medicine minimal inhibitory concentration
As seen from the above table, antimicrobial drug all reduces more than 4 times producing the colibacillary minimal inhibitory concentration of ESBLs, can be judged as Herba Lycopi and have drug resistance inversion effect to producing ESBLs escherichia coli.
In order to further illustrate technical scheme of the present invention, applicant has carried out following specific embodiment:
Embodiment 1
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 12 parts of amoxicillin, 160 parts of Herba Lycopi.
Embodiment 2
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 3 parts of amoxicillin, 180 parts of Herba Lycopi.
Embodiment 3
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 20 parts of amoxicillin, 40 parts of Herba Lycopi.
Embodiment 4
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 20 parts of amoxicillin, 180 parts of Herba Lycopi.
Embodiment 5
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 12 parts of norfloxacins, 120 parts of Herba Lycopi.
Embodiment 6
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 3 parts of norfloxacins, 190 parts of Herba Lycopi.
Embodiment 7
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 25 parts of levofloxacins, 30 parts of Herba Lycopi.
Embodiment 8
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 25 parts of norfloxacins, 190 parts of Herba Lycopi.
Embodiment 9
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 14 parts of sulfamonomethoxine sodium, 20 parts of Herba Lycopi.
Embodiment 10
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 7 parts of sulfamonomethoxine sodium, 160 parts of Herba Lycopi.
Embodiment 11
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 30 parts of sulfamonomethoxine sodium, 160 parts of Herba Lycopi.
Embodiment 12
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 30 parts of sulfamonomethoxine sodium, 10 parts of Herba Lycopi.
Embodiment 13
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 9 parts of florfenicols, 30 parts of Herba Lycopi.
Embodiment 14
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 3 parts of florfenicols, 180 parts of Herba Lycopi.
Embodiment 15
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 20 parts of florfenicols, 10 parts of Herba Lycopi.
Embodiment 16
Contain the compound that Herba Lycopi treats poultry coli-infection disease, formed by the raw material of following weight ratio: 20 parts of florfenicols, 180 parts of Herba Lycopi.
Above-described embodiment 1-embodiment 16 is prepared in accordance with the following methods: Herba Lycopi was pulverized after 60 mesh sieves, as basic material, then with pulverous antimicrobial drug by weight ratio put into blender and mix, and embodiment 2,6,9 and 15 is prepared into powder; Embodiment 1,5,10 and 16 is prepared into tablet, and embodiment 3,7,11 and 13 is prepared into oral liquid; Embodiment 4,8,12 and 14 is prepared into granule.
For the beneficial effect that illustrates that better the present invention can obtain, applicant has carried out following Application Example.
Application Example 1
The efficacy experiment of the compound of embodiment 1-embodiment 4 gained to chicken escherichia coil disease:
Clinical symptoms: Guangxi Yulin chicken house, 20 Day-old Broiler Chickens, there is fragmentary death in chicken group, cuts open the indivedual chickens of inspection and occur the pathological change of bag pericardium liver, typical bacillus coli feature.
Laboratory diagnosis: get pathologic liver and dye sheet, Gram’s staining, micro-Microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.Cultivate by escherichia coli, biochemical test is differentiated, judges that chicken infects for bacillus coli, and pcr amplification, proves to produce the ESBLs drug resistant gene that has TEM type.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, use embodiment 1 according to the addition administration of 1.6g/kg feedstuff for first group, use embodiment 2 according to the addition administration of 6.7g/kg feedstuff for second group, use embodiment 3 according to the addition administration of 0.3g/kg feedstuff for the 3rd group, use embodiment 4 according to the addition administration of 1.2g/kg feedstuff for the 4th group; The 5th group with amoxicillin powder according to the addition administration of 0.12g/kg feedstuff, the 6th group with the thick powder of Herba Lycopi according to the addition administration of 6.7g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Effect feedback: after the chicken group medication of first group to the 4th group, sick chicken feed intake rises, and no longer occurs dead chicken, continues to use 3 days, and chicken group be almost recovered; The chicken group medication of the 5th group is after 2 days, and chicken group majority is still unhealthy, still has indivedual chicken deaths, continues to use 3 days, and chicken death phenomenon is not still effectively controlled; The chicken group medication of the 6th group is after 2 days, and chicken group does not have too large remarkable improvement, continues to use 3 days, and chicken death phenomenon is not still effectively controlled.The visible Herba Lycopi's of containing compound curative effect is better than folk prescription.
Application Example 2
The efficacy experiment of the meat-type duck diarrhoea of the compound of embodiment 5-embodiment 8 gained to 20 ages in days:
Clinical symptoms: duck field, Nanning, 20 age in days meat-type duck, duck group draws watery stools, has obvious indigested feedstuff in feces.A duck group material feeding is not but long, and the serious duck appearance foot gradually of suffering from diarrhoea is individually soft slowly dead.
Cut open inspection pathological changes: the duck that dies of illness dehydration is more serious, indivedual ducks are still very large, duck liver enlargement, hyperemia, and adularescent film on the liver of part duck, air bag muddiness, tentative diagnosis is escherichia coli.
Test therapeutic regimen: morbidity duck group divides seven groups of administrations, use embodiment 5 according to the addition administration of 1.8g/kg feedstuff for first group, use embodiment 6 according to the addition administration of 9.6g/kg feedstuff for second group, use embodiment 7 according to the addition administration of 0.3g/kg feedstuff for the 3rd group, use embodiment 8 according to the addition administration of 1.5g/kg feedstuff for the 4th group; The 5th group with norfloxacin powder according to the addition administration of 0.2g/kg feedstuff, the 6th group of levofloxacin powder be according to the addition administration of 0.2g/kg feedstuff, the 7th group with the thick powder of Herba Lycopi according to the addition administration of 9.6g/kg feedstuff; Above seven groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 2 days, and sick duck is no longer drawn watery stools, feces is shaped, and no longer occurs dead duck, continues to use 3 days, and duck group be almost recovered; The 5th group and the 6th group of medication are after 2 days, and duck group DeGrain, much still draws watery stools, contain indigested feedstuff, continue to use 3 days, some improvement a little, but not good thorough, rare watery stools still occurs, raiser cannot drug withdrawal to these two groups of ducks, have to use the compound of embodiment 6 gained instead, continue to use 2 days, just be almost recovered, re-use 1 day, feces all transfers to normally; The 7th group of medication is after 2 days, and duck does not have too large remarkable improvement, continues to use 3 days, and the duck phenomena of mortality are not still effectively controlled.The visible Herba Lycopi's of containing compound is better than folk prescription to the curative effect of E. coli isolated from ducks.
Application Example 3
The efficacy experiment of the broiler diarrhoea of the compound of embodiment 9-12 gained to 30 ages in days:
Clinical symptoms: Nandan County, Guangxi chicken house, 30 Day-old Broiler Chickens, chicken group draws watery stools, has obvious indigested feedstuff in feces.Indivedual serious chicken appearance gradually of suffering from diarrhoea are slowly dead.
Cut open inspection pathological changes: the chicken that dies of illness dehydration is more serious, indivedual dead chickens are still very large, Hepar Gallus domesticus enlargement, hyperemia, and adularescent film on the liver of part chicken, air bag muddiness, tentative diagnosis is escherichia coli.
Test therapeutic regimen: morbidity chicken group divides six groups of administrations, use embodiment 9 according to the addition administration of 3.1g/kg feedstuff for first group, use embodiment 10 according to the addition administration of 36g/kg feedstuff for second group, use embodiment 11 according to the addition administration of 8g/kg feedstuff for the 3rd group, use embodiment 12 according to the addition administration of 1.8g/kg feedstuff for the 4th group; The 5th group with sulfamonomethoxine sodium powder according to the addition administration of 2g/kg feedstuff, the 6th group with the thick powder of Herba Lycopi according to the addition administration of 36g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 3 days, and sick chicken is no longer drawn watery stools, feces is shaped, and no longer occurs dead chicken, continues to use 2 days, and chicken group be almost recovered; The 5th group of medication is after 3 days, chicken group DeGrain, much still draw watery stools, contain indigested feedstuff, continue to use 2 days, some improvement a little, but thoroughly not good, rare watery stools still occurs, raiser uses the compound of embodiment 16 gained instead, continue to use 3 days, feces all transfers to normally; The 6th group of medication is after 3 days, and chicken does not have too large remarkable improvement, continues to use 2 days, and chicken death phenomenon is not still effectively controlled.The visible Herba Lycopi's of containing compound is better than folk prescription to the curative effect of chicken colibacillosis.
Application Example 4
The efficacy experiment of the piglet diarrhea of embodiment 13-embodiment 16 compounds to 40 ages in days:
Clinical symptoms: pig farm, Nanning, 40 age in days piglets, this swinery after wean is turn-taked, starts to occur diarrhoea, draws watery stools, feces contains indigested feedstuff, pig material feeding but be exactly not grow, indivedual serious diarrhea of pigs dehydrations are dead, do not occur symptoms of emesis, raiser uses multi-medicament, and ideal effect does not all appear in treatment.
Cut open inspection pathological changes: after cuing open inspection, Intestinum Sus domestica wall is poor, especially small intestinal rear end and colon position, intestinal mucosa comes off, intestinal wall hyperemia, hemorrhage.
Laboratory diagnosis: get pathologic liver and dye sheet, Gram’s staining, micro-Microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.Cultivate by escherichia coli, biochemical test is differentiated, judges that piglets infects for bacillus coli, and pcr amplification, proves to produce the ESBLs drug resistant gene that has OXA type.
Test therapeutic regimen: morbidity swinery is divided 6 groups of administrations, use embodiment 13 according to the addition administration of 1g/kg feedstuff for first group, use embodiment 14 according to the addition administration of 15g/kg feedstuff for second group, use embodiment 15 according to the addition administration of 0.36g/kg feedstuff for the 3rd group, use embodiment 16 according to the addition administration of 2.6g/kg feedstuff for the 4th group; The 5th group with florfenicol powder according to the addition administration of 0.24g/kg feedstuff, the 6th group with the thick powder of Herba Lycopi according to the addition administration of 0.12g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 2 days, and swinery is no longer drawn watery stools, feces is shaped, and no longer contains feedstuff in feces, continues to use 3 days swinery recovery from illness; The 5th group of medication is after 2 days, and swinery is still unhealthy, continues to use 3 days, substantially get well, but still draw pasty state feces individually, but drug withdrawal is after 3 days, and recurrence appears in swinery; The 6th group of medication is after 2 days, and swinery, without remarkable improvement, continues to use 3 days, and swinery continues to have loose bowels, and all the other are also more serious individually.The visible Herba Lycopi's of containing compound is better than folk prescription florfenicol and folk prescription Herba Lycopi to swinery curative effect.
Claims (2)
1. a poultry compound medicine that contains Herba Lycopi and florfenicol, is characterized in that, is made up of the raw material of following weight ratio: florfenicol 3-20 part, Herba Lycopi 10-180 part.
2. the poultry compound medicine that contains Herba Lycopi and florfenicol according to claim 1, is characterized in that, described compound is prepared into powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410165137.2A CN103961400A (en) | 2013-03-18 | 2013-03-18 | Compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410165137.2A CN103961400A (en) | 2013-03-18 | 2013-03-18 | Compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310085612.0A Division CN103127508B (en) | 2013-03-18 | 2013-03-18 | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103961400A true CN103961400A (en) | 2014-08-06 |
Family
ID=51231721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410165137.2A Pending CN103961400A (en) | 2013-03-18 | 2013-03-18 | Compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103961400A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306421A (en) * | 2014-11-07 | 2015-01-28 | 广西大学 | Balsamiferou Blumea herb and florfenicol containing compound medicine for livestock and poultry |
| CN106109548A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae and florfenicol |
| CN106109558A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and florfenicol |
| CN106176941A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and florfenicol |
| CN106236836A (en) * | 2016-09-21 | 2016-12-21 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and florfenicol |
| CN113018324A (en) * | 2021-03-30 | 2021-06-25 | 四川省畜牧科学研究院 | Application of dipsacus asperoides extract, composite antibacterial composition, preparation method of composite antibacterial composition and composite antibacterial preparation |
-
2013
- 2013-03-18 CN CN201410165137.2A patent/CN103961400A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 朱金凤等: "牛至油与抗菌药联用体外对产ESBLs大肠杆菌作用的研究初探", 《中兽医医学杂志》 * |
| 李建志: "黑龙江省地产中药泽兰抗菌作用实验研究", 《中医药学报》 * |
| 汤法银等: "牛至油和小糪碱联用对产ESBLs鸡大肠埃希菌的体外抗菌试验", 《中国兽医杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306421A (en) * | 2014-11-07 | 2015-01-28 | 广西大学 | Balsamiferou Blumea herb and florfenicol containing compound medicine for livestock and poultry |
| CN106109548A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae and florfenicol |
| CN106109558A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and florfenicol |
| CN106176941A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and florfenicol |
| CN106236836A (en) * | 2016-09-21 | 2016-12-21 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and florfenicol |
| CN113018324A (en) * | 2021-03-30 | 2021-06-25 | 四川省畜牧科学研究院 | Application of dipsacus asperoides extract, composite antibacterial composition, preparation method of composite antibacterial composition and composite antibacterial preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103127507B (en) | A kind of compound containing Cortex Ilicis Rotundae treatment poultry coli-infection disease | |
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN103127508B (en) | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103961400A (en) | Compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry | |
| CN103961421A (en) | Compound medicine containing radix paeoniae rubra and mequindox for livestock and poultry | |
| CN103301463A (en) | Compound composition containing plumbago zeylanica for treating livestock and poultry escherichia coli infection diseases | |
| CN103948691B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and sulfamonomethoxine sodium | |
| CN103977088A (en) | Compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry | |
| CN103961401A (en) | Compound medicine comprising herba lycopi and sulfamonomethoxine sodium and used for livestock and poultry | |
| CN103948677A (en) | Boneset/amoxicillin-containing compound medicine for livestock and fowl | |
| CN103948656A (en) | Creat/fosfomycin-containing compound medicine for livestock and fowl | |
| CN104027369A (en) | Plumbago zeylanica and norfloxacin containing compound composition for livestock and poultry | |
| CN103948692A (en) | Red paeonia/amikacin-containing compound medicine for livestock and fowl | |
| CN103933544B (en) | A kind of poultry compound medicine containing Herba Andrographis and colistin | |
| CN103933543B (en) | Utilize the method for Herba Andrographis and colistin treatment poultry coli-infection disease | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN104436160A (en) | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry | |
| CN104367601A (en) | Compound medicine containing herba pteridis multifidae and mequindox for livestock and poultry | |
| CN104337847A (en) | Compound medicine containing bracken and fosfomycin for livestock | |
| CN104027370A (en) | Plumbago zeylanica and mequindox containing compound composition for livestock and poultry | |
| CN104027368A (en) | Plumbago zeylanica and doxycycline containing compound composition for livestock and poultry | |
| CN104435013A (en) | Pteris multifida and amikacin-containing compound drug for livestock and poultry | |
| CN104435038A (en) | Balsamiferou blumea herb and mequindox containing compound medicine for livestock and poultry | |
| CN104042651A (en) | Ovate leaf holly bark and mequindox containing compound composition for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140806 |